Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Research

CXCL10 is a prognostic marker for pancreatic adenocarcinoma and tumor microenvironment remodeling

Authors: Yuan Nie, Chao Liu, Qi Liu, Xuan Zhu

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background:

The tumor microenvironment (TME) plays a crucial role in the progression of pancreatic adenocarcinoma (PAAD). However, challenges remain regarding the role played by TME associated genes in the prognosis of PAAD.

Methods:

The scores of tumor infiltrating immune cells (TICs), the immune and stroma scores of 182 PAAD patients in the Cancer Genome Atlas (TCGA) database were determined using CIBERSORT and ESTIMATE calculations. The final genes were identified by protein-protein interaction (PPI) networks and univariate Cox regression of differentially expressed genes. Finally, the correlation between gene expression and TCGA and clinical characteristics of patients in local hospital database was discussed. Gene set enrichment analysis (GSEA), the association between CXCL10 expression and TICs components were conducted.

Results:

In TCGA database and local hospital data, CXCL10 expression was correlated with the survival rate and TNM classification of patients with PAAD. Immune-related activities were enriched in the CXCL10 high expression group, while metabolic pathways were enriched in the CXCL10 low expression group. The expression of CXCL10 correlated with the proportion of TICs. CXCL10 expression was correlated with the proportion of TICs.

Conclusion:

CXCL10 is a potential prognostic marker for PAAD and provide additional insights into the treatment of PAAD based on TME transformation. However, more independent experimentation with the CXCL10 is need.
Appendix
Available only for authorised users
Literature
1.
2.
3.
Christenson ES, Jaffee E, Azad NS. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future[J]. Lancet Oncol. 2020;21(3):e135–45.CrossRefPubMedPubMedCentral
4.
Mittal K, Ebos J, Rini B. Angiogenesis and the tumor microenvironment: vascular endothelial growth factor and beyond[J]. Semin Oncol. 2014;41(2):235–51.CrossRefPubMed
5.
Neesse A, Frese KK, Bapiro TE, et al. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer[J]. Proc Natl Acad Sci U S A. 2013;110(30):12325–30.CrossRefPubMedPubMedCentral
6.
7.
Yamamoto T, Yanagimoto H, Satoi S, et al. Circulating CD4 + CD25 + regulatory T cells in patients with pancreatic cancer[J]. Pancreas. 2012;41(3):409–15.CrossRefPubMed
8.
9.
Lasagni L, Francalanci M, Annunziato F, et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4[J]. J Exp Med. 2003;197(11):1537–49.CrossRefPubMedPubMedCentral
10.
Sahin H, Borkham-Kamphorst E, Do ON, et al. Proapoptotic effects of the chemokine, CXCL 10 are mediated by the noncognate receptor TLR4 in hepatocytes[J]. Hepatology. 2013;57(2):797–805.CrossRefPubMed
11.
Wang S, Li Y, Xing C, et al. Tumor microenvironment in chemoresistance, metastasis and immunotherapy of pancreatic cancer[J]. Am J Cancer Res. 2020;10(7):1937–53.PubMedPubMedCentral
12.
13.
Storz P, Crawford HC. Carcinogenesis of pancreatic ductal Adenocarcinoma[J]. Gastroenterology. 2020;158(8):2072–81.CrossRefPubMed
14.
Hiraoka N, Onozato K, Kosuge T, et al. Prevalence of FOXP3 + regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions[J]. Clin Cancer Res. 2006;12(18):5423–34.CrossRefPubMed
15.
Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival[J]. Nat Med. 2004;10(9):942–9.CrossRefPubMed
16.
Duan X, Deng L, Chen X, et al. Clinical significance of the immunostimulatory MHC class I chain-related molecule A and NKG2D receptor on NK cells in pancreatic cancer[J]. Med Oncol. 2011;28(2):466–74.CrossRefPubMed
17.
18.
Chang DZ, Ma Y, Ji B, et al. Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma[J]. Clin Cancer Res. 2011;17(22):7015–23.CrossRefPubMedPubMedCentral
19.
Antoon R, Wang XH, Saleh AH et al. Pancreatic cancer growth promoted by bone marrow mesenchymal stromal cell-derived IL-6 is reversed predominantly by IL-6 blockade. CYTOTHERAPY 2022 2022-07-01;24(7):699–710.
20.
Xu Y, Liu N, Wei Y et al. Anticancer effects of miR-124 delivered by BM-MSC derived exosomes on cell proliferation, epithelial mesenchymal transition, and chemotherapy sensitivity of pancreatic cancer cells. Aging (Albany NY) 2020 2020-10-11;12(19):19660–19676.
21.
Zischek C, Niess H, Ischenko I et al. Targeting tumor stroma using engineered mesenchymal stem cells reduces the growth of pancreatic carcinoma. ANN SURG 2009 2009-11-01;250(5):747–753.
22.
Bellone G, Novarino A, Chiappino I, et al. Circulating vascular endothelial growth factor and interferon-gamma-inducible protein-10 levels in pancreatic cancer during chemotherapy[J]. Anticancer Res. 2005;25(5):3287–91.PubMed
23.
Antonelli A, Ferrari SM, Giuggioli D, et al. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases[J]. Autoimmun Rev. 2014;13(3):272–80.CrossRefPubMed
24.
25.
Lunardi S, Jamieson NB, Lim SY, et al. IP-10/CXCL10 induction in human pancreatic cancer stroma influences lymphocytes recruitment and correlates with poor survival[J]. Oncotarget. 2014;5(22):11064–80.CrossRefPubMedPubMedCentral
26.
Lunardi S, Lim SY, Muschel RJ, et al. IP-10/CXCL10 attracts regulatory T cells: implication for pancreatic cancer[J]. Oncoimmunology. 2015;4(9):e1027473.CrossRefPubMedPubMedCentral
27.
Blaustein MP. The pump, the exchanger, and the holy spirit: origins and 40-year evolution of ideas about the ouabain-Na(+) pump endocrine system[J]. Am J Physiol Cell Physiol. 2018;314(1):C3–C26.CrossRefPubMed
28.
Ramesh G, Krawczeski CD, Woo JG, et al. Urinary netrin-1 is an early predictive biomarker of acute kidney injury after cardiac surgery[J]. Clin J Am Soc Nephrol. 2010;5(3):395–401.CrossRefPubMedPubMedCentral
Metadata
Title
CXCL10 is a prognostic marker for pancreatic adenocarcinoma and tumor microenvironment remodeling
Authors
Yuan Nie
Chao Liu
Qi Liu
Xuan Zhu
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-10615-w

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Study Protocol

Test, evidence, transition projects in Scotland: developing the evidence needed for transition of effective interventions in cancer care from innovation into mainstream practice

Research

The Effect of immunonutrition in patients undergoing pancreaticoduodenectomy: a systematic review and meta-analysis

Research

Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer

Research

Six polymorphisms in the lncRNA H19 gene and the risk of cancer: a systematic review and meta-analysis

Research

Construction of iron metabolism-related prognostic features of gastric cancer based on RNA sequencing and TCGA database

Research

Plasma ctDNA increases tissue NGS-based detection of therapeutically targetable mutations in lung cancers
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits